Exp Physiol:卵清蛋白诱导的过敏性鼻炎中的MiR-199-3p/Dnmt3a/STAT3信号通路研究

2019-06-10 AlexYang MedSci原创

之前的研究阐释了表观遗传修饰在过敏性鼻炎(AR)中的作用,尤其是DNA甲基化。然而,详细的机制仍旧不清楚。最近,有研究人员利用卵清蛋白诱导的AR小鼠探索了上述详细机制,并且利用行为评分、组胺和其他炎症因子来确定建模是否成功。另外,还利用实时定量、蛋白免疫印迹和亚硫酸氢盐测序PCR(BSP)的双报告子试验检测了相关基因和蛋白的表达、甲基化情况和靶标情况。研究发现,行为评分和分子标记均表明建模成功。D

之前的研究阐释了表观遗传修饰在过敏性鼻炎(AR)中的作用,尤其是DNA甲基化。然而,详细的机制仍旧不清楚。

最近,有研究人员利用卵清蛋白诱导的AR小鼠探索了上述详细机制,并且利用行为评分、组胺和其他炎症因子来确定建模是否成功。另外,还利用实时定量、蛋白免疫印迹和亚硫酸氢盐测序PCR(BSP)的双报告子试验检测了相关基因和蛋白的表达、甲基化情况和靶标情况。研究发现,行为评分和分子标记均表明建模成功。Dnmt3a表达减少,Stat3启动子持续低甲基化且STAT3表达量提高,从而导致lgE和其他炎症因子表达量提高。研究人员预测了Dnmt3a 3'-UTR的microRNA,并通过双报告子试验进行了确定。miR-199-3p拮抗剂能够明显的减弱AR的症状。

最后,研究人员指出,miR-199-3p/Dnmt3a/STAT3信号途径能够参与了OVA诱导的AR,并且miR-199-3p拮抗剂同样能够减弱症状。

原始出处:

Cui X, Guo Y, Wang Q et al. MiR-199-3p/Dnmt3a/STAT3 signaling pathway in the ovalbumin-induced allergic rhinitis. Exp Physiol. 23 May 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650269, encodeId=3278165026996, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jan 31 12:53:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788921, encodeId=6e5a1e8892153, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Nov 10 15:53:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047126, encodeId=4787204e126de, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 10 12:53:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930715, encodeId=cc811930e1504, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jul 05 20:53:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348972, encodeId=b7d713489e288, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524504, encodeId=9dfb152450450, content=<a href='/topic/show?id=5d346162a6' target=_blank style='color:#2F92EE;'>#DNMT3A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6162, encryptionId=5d346162a6, topicName=DNMT3A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed211606244, createdName=zjubiostat, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539746, encodeId=0e911539e46b2, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650269, encodeId=3278165026996, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jan 31 12:53:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788921, encodeId=6e5a1e8892153, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Nov 10 15:53:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047126, encodeId=4787204e126de, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 10 12:53:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930715, encodeId=cc811930e1504, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jul 05 20:53:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348972, encodeId=b7d713489e288, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524504, encodeId=9dfb152450450, content=<a href='/topic/show?id=5d346162a6' target=_blank style='color:#2F92EE;'>#DNMT3A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6162, encryptionId=5d346162a6, topicName=DNMT3A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed211606244, createdName=zjubiostat, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539746, encodeId=0e911539e46b2, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650269, encodeId=3278165026996, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jan 31 12:53:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788921, encodeId=6e5a1e8892153, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Nov 10 15:53:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047126, encodeId=4787204e126de, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 10 12:53:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930715, encodeId=cc811930e1504, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jul 05 20:53:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348972, encodeId=b7d713489e288, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524504, encodeId=9dfb152450450, content=<a href='/topic/show?id=5d346162a6' target=_blank style='color:#2F92EE;'>#DNMT3A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6162, encryptionId=5d346162a6, topicName=DNMT3A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed211606244, createdName=zjubiostat, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539746, encodeId=0e911539e46b2, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1650269, encodeId=3278165026996, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jan 31 12:53:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788921, encodeId=6e5a1e8892153, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Nov 10 15:53:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047126, encodeId=4787204e126de, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 10 12:53:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930715, encodeId=cc811930e1504, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jul 05 20:53:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348972, encodeId=b7d713489e288, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524504, encodeId=9dfb152450450, content=<a href='/topic/show?id=5d346162a6' target=_blank style='color:#2F92EE;'>#DNMT3A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6162, encryptionId=5d346162a6, topicName=DNMT3A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed211606244, createdName=zjubiostat, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539746, encodeId=0e911539e46b2, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-07-05 smallant2002
  5. [GetPortalCommentsPageByObjectIdResponse(id=1650269, encodeId=3278165026996, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jan 31 12:53:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788921, encodeId=6e5a1e8892153, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Nov 10 15:53:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047126, encodeId=4787204e126de, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 10 12:53:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930715, encodeId=cc811930e1504, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jul 05 20:53:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348972, encodeId=b7d713489e288, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524504, encodeId=9dfb152450450, content=<a href='/topic/show?id=5d346162a6' target=_blank style='color:#2F92EE;'>#DNMT3A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6162, encryptionId=5d346162a6, topicName=DNMT3A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed211606244, createdName=zjubiostat, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539746, encodeId=0e911539e46b2, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-12 李研东
  6. [GetPortalCommentsPageByObjectIdResponse(id=1650269, encodeId=3278165026996, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jan 31 12:53:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788921, encodeId=6e5a1e8892153, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Nov 10 15:53:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047126, encodeId=4787204e126de, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 10 12:53:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930715, encodeId=cc811930e1504, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jul 05 20:53:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348972, encodeId=b7d713489e288, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524504, encodeId=9dfb152450450, content=<a href='/topic/show?id=5d346162a6' target=_blank style='color:#2F92EE;'>#DNMT3A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6162, encryptionId=5d346162a6, topicName=DNMT3A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed211606244, createdName=zjubiostat, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539746, encodeId=0e911539e46b2, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-12 zjubiostat
  7. [GetPortalCommentsPageByObjectIdResponse(id=1650269, encodeId=3278165026996, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jan 31 12:53:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788921, encodeId=6e5a1e8892153, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Nov 10 15:53:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047126, encodeId=4787204e126de, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 10 12:53:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930715, encodeId=cc811930e1504, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jul 05 20:53:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348972, encodeId=b7d713489e288, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524504, encodeId=9dfb152450450, content=<a href='/topic/show?id=5d346162a6' target=_blank style='color:#2F92EE;'>#DNMT3A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6162, encryptionId=5d346162a6, topicName=DNMT3A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed211606244, createdName=zjubiostat, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539746, encodeId=0e911539e46b2, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Jun 12 03:53:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]

相关资讯

Allergy Asthma Clin Immunol:屋尘螨过敏性鼻炎的舌下免疫治疗药片研究

最近,有研究人员进行了成本最小化分析来评估利用SQ 屋尘螨舌下免疫治疗(SQ HDM SLIT)来对HDM诱导的过敏性鼻炎进行治疗的经济影响,而在研究所在地区,屋尘螨舌下免疫治疗(HDM SCIT)已经是一个可以选择的疗法。CMA被认为是合适的并且是基于SQ HDM SLIT药片治疗与HDM SCIT具有相当的疗效。研究人员在评估模型中采用了社会视角,包括了药物的相关花费、健康医疗服务和产出损失。

Asian Pac J Allergy Immunol:盐水洗鼻对儿童过敏性鼻炎和哮喘益处研究

哮喘和过敏性鼻炎(AR)是气道慢性炎症疾病并且相互影响着疾病的严重度。最近,有研究人员调查了是否生理盐水洗鼻(NSI)能够改善哮喘和过敏性鼻炎(AR)儿童的气道高反应性和临床参数。研究人员招募了20名AR和哮喘儿童,年龄在6-18岁。患者被随机分成了2组:洗鼻组(8名男孩和2名女孩)和对照组(8名男孩和2名女孩)。洗鼻组每天都进行NSI。所有的参与者接受了为期12周的孟鲁司特,左西替利嗪,吸入糖皮

Int Immunopharmacol:过敏性鼻炎中桔皮素能够促进T细胞分化

桔皮素具有广谱的抗炎症作用。最近,有研究人员评估了是否桔皮素在调控T调节细胞(Tregs)和减弱过敏性鼻炎(AR)中具有功能。研究发现,在AR组中,桔皮素和地塞米松(DXM)给药均能够减弱呼吸道炎症,减少血清OVA诱导的lgE的产生,但是只有桔皮素给药能够恢复细胞因子的平衡。在AR小鼠或者CD4+T细胞分化中,脾脏CD4+CD25+FOXP3+Treg细胞的丰度和FOXP3转录因子水平在桔皮素治疗

Int Arch Allergy Immunol:过敏性鼻炎对鼻腔黏液纤毛清除时间的影响研究

鼻腔黏液纤毛清除是气道中的最重要的保护功能之一。之前的研究探索了过敏性鼻炎(AR)对鼻腔黏液纤毛清除时间(MCT)的影响,但是患者群体小且结果存在矛盾。最近,他们确定了是否AR对MCT具有影响。研究包括了842名AR儿童,总共有96名没有过敏性鼻炎历史的儿童作为对照组。研究发现,与对照相比(平均值±SD:7.25±4.3 ),鼻MCT在AR患者中显著更长(平均值±SD:10.5±5.65分钟)。嗜

Drug Deliv Transl Res:包含壳聚糖基纳米颗粒负载热敏原位凝胶的马来酸氯苯那敏在过敏性鼻炎治疗中的研究

最近,有研究人员制造了一个包含马来酸氯苯那敏(CPM)纳米颗粒的热敏凝胶,进行鼻腔给药从而对过敏性鼻炎进行有效的治疗。研究人员利用沉淀法获得了壳聚糖基纳米颗粒,之后在基于波洛沙姆407和卡波934p的黏附性热可逆凝胶中加入研制的NPs。研制的配方用来评估颗粒的大小、PDI、包封百分比和累积药物渗透百分比。研究发现,NP3配方具有最优的最小颗粒(143.9nm)、最大的包封比例(80.10±0.41

Int J Environ Res Public Health:亚洲糖尿病患者中二肽酰肽酶-4抑制剂与过敏性鼻炎相关性分析

最近,有研究人员尝试评估了二肽酰肽酶-4抑制剂(DPP-4)与过敏性鼻炎在糖尿病患者中可能的相关性。研究人员的研究群体包括了2009年到2012年之间的2型糖尿病(ICD-9-CM 250)患者群体,并分为DPP-4使用者和非使用者。研究人员在多变量逻辑回归分析模型中评估了倾向性评分来对过敏性鼻炎(ICD-9-CM 477.9)进行分析。每个组中包括了6204名患者。研究发现,DDP-4抑制剂使用